Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice

Fabrina Gaspal1, David Withers, Manoj Saini

  • 1MRC Centre for Immune Regulation, Institute for Biomedical Research, Birmingham Medical School, Birmingham B15 2TT, England, UK.

Insights

Tumor necrosis factor receptors OX40 and CD30 are essential for CD4 T cell-mediated autoimmune tissue damage. Blocking these signals prevents autoimmune disease in FoxP3-deficient mice, suggesting combination therapies for human autoimmune conditions.

Area of Science:

  • Immunology
  • Autoimmunity
  • T cell biology

Background:

  • Signaling through tumor necrosis factor receptors OX40 and CD30 is critical for CD4 memory responses.
  • Regulatory CD4 T cells, dependent on the transcription factor FoxP3, normally prevent autoimmune disease.

Purpose of the Study:

  • To investigate the role of OX40 and CD30 signaling in CD4 effector-mediated autoimmune tissue damage.
  • To determine if blocking OX40 and CD30 signaling can prevent autoimmune disease in the absence of regulatory T cells.

Main Methods:

  • Utilized mice deficient in the forkhead transcription factor FoxP3 (lacking regulatory CD4 T cells).
  • Generated mice deficient in OX40, CD30, or both.
  • Administered blocking antibodies against OX40 and CD30 ligands.

Main Results:

  • FoxP3-deficient mice lacking both OX40 and CD30 signaling developed normally and did not exhibit autoimmune disease.
  • Absence of OX40 signaling played a dominant role, but deficiency in OX40 alone eventually led to lethal disease.
  • Blocking antibodies to OX40 and CD30 ligands abrogated autoimmune disease mediated by FoxP3-deficient T cells.

Conclusions:

  • OX40 and CD30 signals are essential for the development of CD4-dependent autoimmunity.
  • Combination therapies targeting OX40 and CD30 may be effective in treating human autoimmune diseases.

Related Concept Videos